Supportive Care in Cancer

, Volume 23, Issue 5, pp 1197–1199 | Cite as

Measurement of chemotherapy-induced alopecia—time to change

  • C. J. G. van den Hurk
  • J. Winstanley
  • A. Young
  • F. Boyle
Commentary

Abstract

Data on chemotherapy-induced alopecia (CIA) as a side effect of cancer treatment are scarce. CIA is given minimal attention in clinical trials and in the literature. However, when asking the patients with cancer for their opinion, CIA appears to have a major impact, particularly on body image and quality of life. Currently, there is no commonly used measure to evaluate CIA; It is time to improve the management and measurement of CIA.

Keywords

Alopecia Chemotherapy Side effect Data quality 

References

  1. 1.
    Rosman S (2004) Cancer and stigma: experience of patients with chemotherapy-induced alopecia. Patient Educ Couns 52(3):333–339CrossRefPubMedGoogle Scholar
  2. 2.
    World Health Organisation (1979) Handbook for reporting results of cancer treatment, vol 48. WHO Offset Publ, GenevaGoogle Scholar
  3. 3.
    Institute NC (2010) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm).
  4. 4.
    van den Hurk CJ, Breed WP, Nortier JW (2012) Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. Support Care Cancer 20(12):3255–3260CrossRefPubMedGoogle Scholar
  5. 5.
    Breed WPM, van den Hurk CJG, Peerbooms M (2011) Presentation, impact and prevention of chemotherapy-induced hair loss; scalp cooling potentials and limitations. Expert Rev Dermatol 6:109–125CrossRefGoogle Scholar
  6. 6.
    Peerbooms M, Breed WPM, van den Hurk CJG (2015 (accepted for publication)) Familiarity, opinions, experiences and knowledge about scalp cooling—a Dutch survey among breast cancer patients and oncological professionals. Asia-Pacific J Oncol NursingGoogle Scholar
  7. 7.
    Hurk van den CJG (2013) Safety and effectiveness of scalp cooling in cancer patients undergoing cytotoxic treatment. Thesis. Leiden University Medical Center. LeidenGoogle Scholar
  8. 8.
    Mulders M, Vingerhoets A, Breed W (2008) The impact of cancer and chemotherapy: perceptual similarities and differences between cancer patients, nurses and physicians. Eur J Oncol Nurs 12(2):97–102CrossRefPubMedGoogle Scholar
  9. 9.
    Hilton S, Hunt K, Emslie C, Salinas M, Ziebland S (2008) Have men been overlooked? A comparison of young men and women's experiences of chemotherapy-induced alopecia. Psycho-Oncology 17(6):577–583CrossRefPubMedGoogle Scholar
  10. 10.
    van den Hurk CJ, Mols F, Vingerhoets AJ, Breed WP (2010) Impact of alopecia and scalp cooling on the well-being of breast cancer patients. Psycho-Oncology 19(7):701–709CrossRefPubMedGoogle Scholar
  11. 11.
    Del Mastro L, Venturini M, Lionetto R, Carnino F, Guarneri D, Gallo L, Contu A, Pronzato P, Vesentini L, Bergaglio M, Comis S, Rosso R (2001) Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group. J Clin Oncol 19(8):2213–2221PubMedGoogle Scholar
  12. 12.
    Zielinski C, Beslija S, Mrsic-Krmpotic Z, Welnicka-Jaskiewicz M, Wiltschke C, Kahan Z, Grgic M, Tzekova V, Inbar M, Cervek J, Chernozemsky I, Szanto J, Spanik S, Wagnerova M, Ghilezan N, Pawlega J, Vrbanec D, Khamtsov D, Soldatenkova V, Brodowicz T (2005) Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. J Clin Oncol 23(7):1401–1408CrossRefPubMedGoogle Scholar
  13. 13.
    Brufman G, Colajori E, Ghilezan N, Lassus M, Martoni A, Perevodchikova N, Tosello C, Viaro D, Zielinski C (1997) Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group. Ann Oncol 8(2):155–162Google Scholar
  14. 14.
    van den Hurk CJ, van den Akker-van Marle ME, Breed WP, van de Poll-Franse LV, Nortier JW, Coebergh JW (2014) Cost-effectiveness analysis of scalp cooling to reduce chemotherapy-induced alopecia. Acta Oncol 53(1):80–87CrossRefPubMedGoogle Scholar
  15. 15.
    Kluger N, Jacot W, Frouin E, Rigau V, Poujol S, Dereure O, Guillot B, Romieu G, Bessis D (2012) Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. Ann Oncol 23(11):2879–2884CrossRefPubMedGoogle Scholar
  16. 16.
    Vleut RE, van Poppel JE, Dercksen MW, Peerbooms M, Houterman S, Breed WP (2013) Hair mass index obtained by cross-section trichometry: an objective and clinically useful parameter to quantify hair in chemotherapy-induced alopecia. Support Care Cancer 21(7):1807–1814CrossRefPubMedGoogle Scholar
  17. 17.
    Kuderer NM, Wolff AC (2014) Enhancing therapeutic decision making when options abound: toxicities matter. J Clin Oncol 32(19):1990–1993CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • C. J. G. van den Hurk
    • 1
  • J. Winstanley
    • 2
  • A. Young
    • 3
  • F. Boyle
    • 2
  1. 1.Netherlands Comprehensive Cancer OrganisationEindhovenThe Netherlands
  2. 2.Patricia Ritchie Centre for Cancer Care and ResearchMater Hospital and University of SydneySydneyAustralia
  3. 3.Warwick Medical SchoolUniversity of WarwickCoventryUK

Personalised recommendations